Literature DB >> 28581024

Blomia tropicalis allergen 5 (Blo t 5) T-cell epitopes and their ability to suppress the allergic immune response.

Kenneth H Wong1,2, Qian Zhou1,2, Nayana Prabhu1,2, Kazuki Furuhashi1, Yen Leong Chua1,2, Gijsbert M Grotenbreg1,2,3, David M Kemeny1,2.   

Abstract

Blomia tropicalis is the major asthma allergen in the tropics comparable to Dermatophagoides pteronyssinus. However, little is known about the B. tropicalis epitopes recognized by T cells. Our aim was to identify the T-cell epitopes in the major B. tropicalis allergen, Blo t 5, and investigate the potential of the corresponding peptides to inhibit the allergic inflammatory lung response. C57BL/6 mice were immunized with plasmid DNA encoding Blo t 5 and T-cell epitopes identified using the interferon-γ ELISPOT assay with 15-mer overlapping peptides. C57BL/6 mice were sensitized with bone-marrow-derived dendritic cells (BMDC) pulsed with Blo t 5 allergen followed by intranasal Blo t 5 challenge. Two H-2b restricted epitopes (Bt576-90 and Bt5106-115 ) were recognized by CD4 T cells specific for Blo t 5, but no CD8 epitopes were identified. In mice sensitized with Blo t 5-pulsed BMDC and challenged with intranasal Blo t 5 Bt576-90 and Bt5106-115 , peptide-specific CD4 T cells were found to secrete the T helper type 2 cytokines interleukin-5 and interleukin-13. Intradermal administration of synthetic peptides encoding the identified T-cell epitopes suppressed allergic airway inflammation to further allergen challenges. Hence, we have identified novel CD4 T-cell epitopes specific for Blo t 5 and demonstrated that these peptides could be employed therapeutically to suppress the T-cell response in a murine model of allergic airway inflammation.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Allergy; Blomia tropicalis; DNA vaccine; mouse model

Mesh:

Substances:

Year:  2017        PMID: 28581024      PMCID: PMC5588770          DOI: 10.1111/imm.12772

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Induction of T cell anergy by low numbers of agonist ligands.

Authors:  L C Korb; S Mirshahidi; K Ramyar; A A Sadighi Akha; S Sadegh-Nasseri
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

2.  Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1.

Authors:  G F Hoyne; M J Dallman; J R Lamb
Journal:  Int Arch Allergy Immunol       Date:  1999 Feb-Apr       Impact factor: 2.749

3.  Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models.

Authors:  Cindy L Zuleger; Xiaoyan Gao; Melissa S Burger; Qili Chu; Lendon G Payne; Dexiang Chen
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

Review 4.  The Blomia tropicalis allergens.

Authors:  Kaw Yan Chua; Nge Cheong; I-Chun Kuo; Bee Wah Lee; Fong Cheng Yi; Chiung-Hui Huang; Lip Nyin Liew
Journal:  Protein Pept Lett       Date:  2007       Impact factor: 1.890

5.  Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma.

Authors:  T J Huang; P A MacAry; P Eynott; A Moussavi; K C Daniel; P W Askenase; D M Kemeny; K F Chung
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

Review 6.  Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products.

Authors:  W W Busse; R L Coffman; E W Gelfand; A B Kay; L J Rosenwasser
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

7.  T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.

Authors:  Adrienne Verhoef; Clare Alexander; A Barry Kay; Mark Larché
Journal:  PLoS Med       Date:  2005-03-29       Impact factor: 11.069

8.  Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner.

Authors:  Erik Wambre; Jonathan H DeLong; Eddie A James; Nadia Torres-Chinn; Wolfgang Pfützner; Christian Möbs; Stephen R Durham; Stephen J Till; David Robinson; William W Kwok
Journal:  J Allergy Clin Immunol       Date:  2013-12-25       Impact factor: 10.793

9.  Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35.

Authors:  D M Moldaver; M S Bharhani; J N Wattie; R Ellis; H Neighbour; C M Lloyd; M D Inman; M Larché
Journal:  Mucosal Immunol       Date:  2013-08-14       Impact factor: 7.313

10.  Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression.

Authors:  John D Campbell; Karen F Buckland; Sarah J McMillan; Jennifer Kearley; William L G Oldfield; Lawrence J Stern; Hans Grönlund; Marianne van Hage; Catherine J Reynolds; Rosemary J Boyton; Stephen P Cobbold; A Barry Kay; Daniel M Altmann; Clare M Lloyd; Mark Larché
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more
  3 in total

1.  Corrigendum.

Authors: 
Journal:  Immunology       Date:  2018-03       Impact factor: 7.397

2.  Storage Mite Precision Allergy Molecular Diagnosis in the Moderate-to-Severe T2-High Asthma Phenotype.

Authors:  Ruperto González-Pérez; Paloma Poza-Guedes; Fernando Pineda; Miriam Castillo; Inmaculada Sánchez-Machín
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

3.  A hybrid of two major Blomia tropicalis allergens as an allergy vaccine candidate.

Authors:  Eduardo Santos da Silva; Lorenz Aglas; Carina Silva Pinheiro; Emília M M de Andrade Belitardo; Elisânia Fontes Silveira; Sara Huber; Rogério Tanan Torres; Michael Wallner; Peter Briza; Peter Lackner; Josef Laimer; Luis Gustavo C Pacheco; Álvaro A Cruz; Neuza Maria Alcântara-Neves; Fatima Ferreira
Journal:  Clin Exp Allergy       Date:  2020-05-13       Impact factor: 5.018

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.